Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01820624 · ClinicalTrials.gov registry record · Phase 1
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Paolo Caimi, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01820624 is a Phase 1 study that has completed, run by Paolo Caimi, MD. The registered enrollment target is 12 participants.
The verdict
NCT01820624, a Phase 1 study, has completed, sponsored by Paolo Caimi, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of tretinoin when given together with lithium carbonate in treating patients with relapsed or refractory acute myeloid leukemia. Lithium carbonate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tretinoin may help \[type of cancer\] cells become more like normal cells, and to grow and spread more slowly. Giving lithium carbonate together with tretinoin may kill more cancer cells
Interventions
- OTHER laboratory biomarker analysis
- DRUG lithium carbonate
- DRUG tretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-04-30 |
| Est. Completion | 2015-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01820624
The ClinicalTrials.gov registry entry for NCT01820624 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paolo Caimi, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01820624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01820624 about?
NCT01820624 is a clinical study titled "Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I trial studies the side effects and best dose of tretinoin when given together with lithium carbonate in treating patients with relapsed or refractory acute myeloid leukemia. Lithium carbonate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tre...
What is the current status of trial NCT01820624?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-04-30. Estimated completion is 2015-11-13.
What interventions are being tested in trial NCT01820624?
The interventions under investigation include: laboratory biomarker analysis (OTHER), lithium carbonate (DRUG), tretinoin (DRUG).
Who is sponsoring clinical trial NCT01820624?
This trial is sponsored by Paolo Caimi, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.